Literature DB >> 7579329

High prevalence of nonsense, frame shift, and splice-site mutations in 16 patients with full-blown Wiskott-Aldrich syndrome.

G S Wengler1, L D Notarangelo, S Berardelli, G Pollonni, P Mella, A Fasth, A G Ugazio, O Parolini.   

Abstract

Wiskott-Aldrich syndrome (WAS) is a fully penetrant X-linked recessive disorder characterized by immunodeficiency, thrombocytopenia, and severe eczema. WAS is a life-threatening disease, with a poor quality of life and high mortality rate in childhood. The gene responsible for the disease has been localized to the proximal short arm of the X-chromosome and recently isolated through positional cloning and named WAS protein (WASP). We have characterized 17 WAS families. We have developed a rapid, nonradioactive screening protocol for identifying WASP gene alterations in genomic DNA. Our method allows simultaneous evaluation of single strand confirmation polymorphism and heteroduplex formation. We have identified 15 novel mutations that involve single basepair changes, or small insertions or deletions, all of which result in premature stop cordon, frame shift with secondary premature stop codon, or splice site defect. These studies document the considerable heterogeneity of the location of mutations in the WASP gene causing full-blown WAS and show the efficiency and rapidity of a screening approach for mutation identification in WAS that will be useful for carrier detection and prenatal diagnosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579329

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  The Wiskott-Aldrich syndrome.

Authors:  H D Ochs
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 8.667

2.  Mutational analysis of the WASP gene in 2 Korean families with Wiskott-Aldrich syndrome.

Authors:  Eun-Kyeong Jo; Takeshi Futatani; Hirokazu Kanegane; Takeo Kubota; Young-Ho Lee; Jin-A Jung; Chang-Hwa Song; Jeong-Kyu Park; Shigeaki Nonoyama; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

Review 3.  The Wiskott-Aldrich syndrome.

Authors:  H D Ochs
Journal:  Springer Semin Immunopathol       Date:  1998

4.  Clinical aspects and genetic analysis of taiwanese patients with wiskott-Aldrich syndrome protein mutation: the first identification of x-linked thrombocytopenia in the chinese with novel mutations.

Authors:  Wen-I Lee; Jing-Long Huang; Tang-Her Jaing; Kang-Hsi Wu; Yin-Hsiu Chien; Kuei-Wen Chang
Journal:  J Clin Immunol       Date:  2010-03-16       Impact factor: 8.317

5.  Studies of the expression of the Wiskott-Aldrich syndrome protein.

Authors:  D M Stewart; S Treiber-Held; C C Kurman; F Facchetti; L D Notarangelo; D L Nelson
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

6.  Mutations in Drosophila enabled and rescue by human vasodilator-stimulated phosphoprotein (VASP) indicate important functional roles for Ena/VASP homology domain 1 (EVH1) and EVH2 domains.

Authors:  S M Ahern-Djamali; A R Comer; C Bachmann; A S Kastenmeier; S K Reddy; M C Beckerle; U Walter; F M Hoffmann
Journal:  Mol Biol Cell       Date:  1998-08       Impact factor: 4.138

7.  Phenotypic and genotypic correction of WASP gene mutation in Wiskott-Aldrich syndrome by unrelated cord blood stem cell transplantation.

Authors:  Young-Ho Lee; Yeon-Jung Lim; Su-Ah Shin; Chang-Hwa Song; Eun-Kyeong Jo; Jin-A Jung; Ha-Baik Lee
Journal:  J Korean Med Sci       Date:  2009-07-30       Impact factor: 2.153

8.  Tryptic peptide screening for primary immunodeficiency disease by LC/MS-MS.

Authors:  Sandra A Kerfoot; Sunhee Jung; Karin Golob; Troy R Torgerson; Si Houn Hahn
Journal:  Proteomics Clin Appl       Date:  2012-08       Impact factor: 3.494

9.  A familial case of Wiskott-Aldrich Syndrome with a hotspot mutation in exon 2 of the WAS Gene.

Authors:  Sook Kyung Park; Chun Soo Kim; Dae Kyu Song; Joo Young Kim; In Jang Choi; Dae Kwang Kim
Journal:  J Korean Med Sci       Date:  2007-12       Impact factor: 2.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.